Addiction

Prevalence of New Psychoactive Substances Use

Prevalence of New Psychoactive Substances Use Among Outpatient of Addiction Management Clinic in Assiut University Hospital

All participant will subjected to the following:
Special sheet designed for the study in department of neurology and psychiatry at Assiut University hospital asking about spychoactive substance use regarding to type, amount, duration,cause of use, and cause for stoppage.
Addiction severity index Urinary drug screen

AAEsraa

Princible investigator

Assiut University

IFF flavor 316 282, Paracetamol, Pseudoephedrine : Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine

Upper Respiratory Infections

Sex: Female, Male

Region of Enrollment

Intensity of warming sensation felt by subjects between predose to 1 minute postdose where 0 = no warming sensation and 100 = strongest possible warming sensation

Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Pseudoephedrine 30 mg Per 30 ml Syrup

How do you like the warming sensation you have experienced for this product?
Possible responses are :
Like extremely Like very much Like moderately Like slightly Neither like nor dislike Dislike slightly Dislike moderately Dislike very much Dislike extremely

Subject Acceptability of the Syrup

Number of participants with adverse events.

Safety and Tolerability of the Syrup

Overall Study

Clinical Project Leader

Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine

IFF flavor 316 282, Paracetamol, Pseudoephedrine

Algorithme Pharma

Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI

An Open Label, In-use Study to Assess the Warming Sensation, Acceptability and Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup Given as a 30 ml Single Dose in Subjects Suffering From Symptoms of an Upper Respiratory Tract Infection

Novartis

Novartis Consumer Health

Common Cold

Headache

Nasal Congestion

Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime [Paracetamol (500 mg) and Pseudoephedrine (30 mg)]

Pseudoephedrine/Paracetamol

JJCPPW Investigational Site

Efficacy and Safety of Sinutab on Subjects in the Setting of a Common Cold

A Community Pharmacy Based Investigation in the Self-Medication Area Efficacy and Safety of Sinutab and Pseudoephedrine on Subjects With Nasal Congestion Accompanied by Headache in the Setting of a Common Cold

McNeil AB